Top Line Results Expected in the Fourth Quarter of 2026 - WAYNE, Pa., March 18, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused ...
Almirall, S.A. (ALM), a global biopharmaceutical company focused on medical dermatology, today announced positive, top-line results from the pivotal Phase 3 ADorable-1 trial evaluating efficacy and ...
Phase 3 ADorable-1 trial results show lebrikizumab-libkz provides skin clearance and itch relief in children with moderate to severe atopic dermatitis.
Eli Lilly and Company (NYSE: LLY) today announced positive, topline results from the Phase 3 ADorable-1 trial evaluating the safety and efficacy of EBGLYSS (lebrikizumab-lbkz) in pediatric patients ...
StudyFinds on MSN
The physics of eczema: A math model predicts the minimum dose to control severe flares
In A Nutshell Researchers used computer modeling and physics-based math to calculate the minimum antibiotic and moisturizer doses needed to push severe eczema into remission and keep it there. The ...
What exactly is severe AD? AD is the most common type of eczema. When this eczema becomes severe, a person has patches of skin that are red, swollen, and unbearably itchy. The patches of AD can weep ...
A new study led by investigators at National Jewish Health and published in Annals of Allergy, Asthma & Immunology shows that ...
Eli Lilly’s phase 3 ADorable-1 trial of Ebglyss in paediatric patients with moderate-to-severe atopic dermatitis meets primary and key secondary endpoints: Indianapolis Tuesday, ...
Pfizer Inc. (NYSE: PFE) today announced positive topline results from a Phase 2 study investigating tilrekimig (PF-07275315) ...
Please provide your email address to receive an email when new articles are posted on . Percentages of patients with at least one atopic comorbidity ranged from 69.9% to 75.4%. Percentages of patients ...
Patients with atopic dermatitis (AD) had a lower risk for major adverse cardiovascular events (MACE) than the general population, and this risk was significantly lower than that of patients with ...
Background: Chronic actinic dermatitis (CAD) is a rare photosensitivity disorder with scant epidemiologic data. Objective: To evaluate demographic data and results of photopatch and patch tests over a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results